文献速递临床试验与 GCP

胃安颗粒治疗慢性萎缩性胃炎的有效性与安全性:随机双盲安慰剂对照多中心临床试验的研究方案

Efficacy and safety of Elian Granules in treating chronic atrophic gastritis: study protocol for a randomized, double-blind, placebo-controlled, multicenter clinical trial.
PubMed 文献 · Trials · 2022-05-24

本研究为一项II期随机、双盲、安慰剂对照、多中心临床试验,计划纳入240例慢性萎缩性胃炎伴或不伴肠上皮化生患者,按1:1比例分配至治疗组或安慰剂对照组。试验药物或安慰剂以沸水冲服,每次2小袋(24.2 g),每日两次,餐后半小时服用,疗程24周。主要结局为基于OLGA/OLGIM分期系统观察6个月后胃黏膜组织学变化,次要结局包括基于消化不良症状评分和生活质量量表的评估。

要点

  • 本试验为II期随机双盲安慰剂对照多中心临床试验,计划纳入240例慢性萎缩性胃炎伴或不伴肠上皮化生患者。
  • 试验药物或安慰剂每次2小袋(24.2 g),每日两次,餐后半小时沸水冲服,疗程24周。
  • 主要结局为基于OLGA/OLGIM分期系统观察6个月后胃黏膜组织学变化。

核心结论

  • 本试验旨在以随机、双盲、安慰剂对照、多中心方式评估胃安颗粒的有效性与安全性,该试验或可为III期临床试验提供证据,并为慢性萎缩性胃炎的治疗提供一种替代选择。

研究设计与样本

  • 本研究为一项II期、随机、双盲、安慰剂对照、多中心临床试验。
  • 计划纳入240例 participant,按1:1比例分配至治疗组或安慰剂对照组。
  • 试验药物或安慰剂以沸水冲服,每次2小袋(24.2 g),每日两次,餐后半小时服用,疗程24周。

关键数值与推荐

  • 主要结局为基于OLGA/OLGIM分期系统观察伴或不伴肠上皮化生的萎缩性胃炎患者6个月后胃黏膜组织学变化。
  • 次要结局包括基于消化不良症状评分和生活质量量表的评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multifocal atrophic gastritis and intestinal metaplasia are considered to be important links in the gastric precancerous cascade. However, there are no specific drugs for these conditions. Although many studies have shown that traditional Chinese medicine is effective with no serious side effects, these studies have not been scientifically rigorous trials. Our aim is to design a high-quality trial for a Chinese patent medicine, Elian Granules, to investigate its efficacy and safety in treating patients with chronic atrophic gastritis with or without intestinal metaplasia. METHODS: This is a phase II, randomized, double-blind, placebo-controlled, multicenter clinical trial. A total of 240 participants will be assigned to a treatment or placebo control group in a 1:1 ratio. The experimental drug or placebo will be taken with boiling water, two small bags (24.2 g) each time, twice a day, half an hour after a meal, for 24 weeks. The primary outcome is the observation of histological changes in the gastric mucosa of patients with atrophic gastritis with or without intestinal metaplasia after 6 months based on the OLGA/OLGIM staging systems. The secondary outcomes include the assessment of dyspepsia and quality of life based on the dyspepsia symptom score and the quality-of-life scale. DISCUSSION: This study is designed to evaluate the efficacy and safety of Elian Granules in a randomized, double-blind, placebo-controlled, multicenter manner. This trial may not only provide evidence for a phase III clinical trial, but also an alternative option for the treatment of chronic atrophic gastritis (CAG). TRIAL REGISTRATION: Registry Platform For Evidence-Based Traditional Chinese Medicine ChiMCTR2000003929 . Registered on 13 September 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gu Z, Jia Q, Cong J, et al. Efficacy and safety of Elian Granules in treating chronic atrophic gastritis: study protocol for a randomized, double-blind, placebo-controlled, multicenter clinical trial. Trials. 2022. PMID: 35610625. doi:10.1186/s13063-022-06395-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。